; and (4) include the dissemination of scientific and evidence-based vaccine-related information, such as— (A) advancements in evidence-based research related to diseases that may be prevented by vaccines and vaccine development; (B) information on vaccinations for individuals and communities, including individuals for whom vaccines are not recommended by the Advisory Committee for Immunization Practices, and the effects of low vaccination rates within a community on such individuals; (C) information on diseases that may be prevented by vaccines; and (D) information on vaccine safety and the systems in place to monitor vaccine safety. (e) Evaluation The Secretary shall— (1) establish benchmarks and metrics to quantitatively measure and evaluate the campaign under this section; (2) conduct qualitative assessments regarding the campaign under this section; and (3) prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate an evaluation of the campaign under this section. (f) Supplement not supplant Funds made available to carry out this section shall be used to supplement and not supplant other Federal, State, local, and Tribal public funds provided for activities described in this section. (g) Authorization of appropriations There is authorized to be appropriated to carry out this section $200,000,000 for the period of fiscal years 2021 through 2025. . (b) Grants to address vaccine-preventable diseases Section 317 of the Public Health Service Act ( 42 U.S.C. 247b ) is amended— (1) in subsection (k)— (A) in paragraph (1)— (i) in subparagraph (C), by striking ; and at the end and inserting a semicolon; (ii) in subparagraph (D), by striking the period at the end and inserting a semicolon